In Between the FDA and Pharma, People Wait for Treatments
It's easy to be skeptical of drug companies. But those of us with polycystic kidney disease, a potentially fatal genetic disorder, stringent FDA regulation seems to be taking away hope.
Bill Brazell
Bill Brazell is a partner at the business-consulting firm WIT Strategy and a former board member of the PKD Foundation, an organization that promotes polycystic kidney disease research and education.